Pfizer Investor Presentation — December 2021

Document content

1 Confidential Breakthroughs that change patients’ livesInflammation &

Immunology Investor Day

December 13, 2021Forward -Looking Statements

This presentation and our discussions during this conference call will include forward -looking statements and forward -looking in formation that

are subject to substantial risks and uncertainties, many of which are beyond our control, that could cause actual results to differ materially from

those expressed or implied by such statements and information. We include forward-looking statements about, among other topics, Pfizer’s

Inflammation & Immunology pipeline, inline products and product candidates, including anticipated regulatory submissions, dat a read-outs, study

starts, approvals, clinical trial results and other developing data that become available, revenue contribution, growth, perf ormance, timing of

exclusivity and potential benefits; anticipated operating and financial performance; capital allocation objectives; the proposed acquisition of

Arena Pharmaceuticals, Inc. by Pfizer; the benefits of the proposed transaction; future opportunities and strategies; growth potential; and

expectations for Arena's product pipeline and product candidates, including expected best -in-class and growth potential. Among o ther things,

statements regarding growth; the development or commercial potential of the product pipeline, inline products, product candid ates and additional

indications, including expected clinical trial protocols, the timing of the initiation and progress of clinical trials and da ta read-outs from trials; the

timing for the submission of applications for and receipt of regulatory approvals; and expected breakthrough, best or first -in-class or blockbuster

status of products are forward-looking and are estimates that are subject to change and clinical trial and regulatory success. T hese statements